drugset
Drugs / AG0301-COVID19
last change Aug 2021 re-read 3 minutes ago

AG0301-COVID19

Vaccine

Developed for
COVID-19
Investigated by
AnGes, Inc. · Japan Agency for Medical Research and Development

Trials 1

today NCT04463472 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04463472 Jun → Sep 2020 COVID-19 AnGes, Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AG0301-COVID19 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04463472 ↗
Modality Vaccine “COVID-19 DNA Vaccine” NCT04463472 ↗
Route Intramuscular “intramuscular (IM)” NCT04463472 ↗